ResultsIQ

ResultsIQ › Latest results › Archean Chemical Industries Limited

Archean Chemical Industries Limited Q2 FY26 results deck summary

NSE: ACI · BSE: 543657

Results deck of 17 Nov 2025, summarised by AI from the filing.

Q2 FY26 standalone total income ₹2,317.8 mn and PAT ₹384.6 mn; SiCSem received ISM approval for SiC fab in August 2025

Key takeaways

  1. Guidance Investment in Offgrid Energy Labs expected to be complete in FY26
  2. Semiconductor milestone SiCSem received ISM approval on August 12, 2025 for SiC fab; groundbreaking held in November 2025
  3. Growth driver Acume Chemicals bromine derivatives fully operational with PTA Synthesis and CBF contributing to revenue
  4. Risk Largest customer contributed 40% of H1FY26 revenue

Original filing on BSE

Archean Chemical Industries Limited Q1 FY27 results

As filed: Revenue ₹327 cr (+12% year on year), EBITDA ₹67.3 cr (−14% year on year), PAT ₹30.4 cr (−24% year on year), EBITDA margin 20.6% (−616 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹301 cr (−13% year on year), EBITDA ₹43.7 cr (−50% year on year), PAT ₹12.2 cr (−77% year on year), EBITDA margin 14.5% (−1,000 bps). Score 16 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 1000 bps year on year. Other income 34% of PBT. Profit fell 49% from last quarter. Share price after the results: −15.0% in 30 days (Nifty 500: −3.0%).
  • Q3 FY26: Revenue ₹255 cr (+5% year on year), EBITDA ₹54.4 cr (−32% year on year), PAT ₹24.0 cr (−50% year on year), EBITDA margin 21.4% (−1,000 bps). Score 34 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 1000 bps year on year. Profit fell 17% from last quarter. Share price after the results: −7.1% in 30 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹233 cr (−3% year on year), EBITDA ₹64.0 cr (−14% year on year), PAT ₹29.0 cr (+81% year on year), EBITDA margin 27.5% (−337 bps). Score 60 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well above it. EBITDA margin fell 337 bps year on year. Revenue fell 20% from last quarter. Share price after the results: −22.0% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹292 cr (+37% year on year), EBITDA ₹78.0 cr (+8% year on year), PAT ₹40.0 cr (−11% year on year), EBITDA margin 26.7% (−709 bps). Score 59 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin fell 709 bps year on year. Revenue fell 16% from last quarter. Share price after the results: −1.2% in 29 days (Nifty 500: −0.3%).
  • Q4 FY25: Revenue ₹346 cr (+22% year on year), EBITDA ₹88.0 cr (0% year on year), PAT ₹54.0 cr (−7% year on year), EBITDA margin 25.4% (−555 bps). Score 67 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 555 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +3.5% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹242 cr (−41% year on year), EBITDA ₹80.0 cr (−45% year on year), PAT ₹48.0 cr (−53% year on year), EBITDA margin 33.1% (−229 bps). Score 23 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 229 bps year on year.
  • Q2 FY25: Revenue ₹240 cr (−17% year on year), EBITDA ₹74.0 cr (−23% year on year), PAT ₹16.0 cr (−28% year on year), EBITDA margin 30.8% (−227 bps). Score 2 of 100, Below trend. EBITDA margin fell 227 bps year on year. Other income 48% of PBT. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Archean Chemical Industries Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.